A consortium of Neurent Medical Ltd (a BioInnovate Ireland spin out) and the Biggs lab at CÚRAM will benefit from €2.8 million in research funding following the recent announcement of the Government’s Disruptive Technologies Innovation Fund. The project, ARDENT II will create a new therapy for patients suffering from rhinitis, an inflammatory disease which presents as nasal congestion, rhinorrhoea, sneezing and nasal itching. Congestion and rhinorrhoea are the two most impactful symptoms on a patient’s quality of life, which are usually present lifelong. Affecting tens of millions of patients worldwide, an effective treatment does not exist for moderate or severe suffers, creating a multi-billion-euro opportunity for disruptive technologies. Funding which will be invested in the development of a new medical device technology, to address this inflammatory nasal condition through an innovative neuromodulation approach.